Abe, Seiichiro http://orcid.org/0000-0002-2736-6921
Takizawa, Kohei
Oda, Ichiro
Mizusawa, Junki
Kadota, Tomohiro
Ono, Hiroyuki
Hasuike, Noriaki
Yano, Tomonori
Yamamoto, Yoshinobu
Horiuchi, Yusuke
Nagata, Shinji
Yoshikawa, Takaki
Terashima, Masanori
Muto, Manabu
Funding for this research was provided by:
Grants-in-Aid for Cancer Research (20S-3, 20S-6, 26-A-4)
the National Cancer Center Research and Development Fund (23-A-16, 23-A-19, 26-A-4 and 29-A-3)
Health and Labour Science Research Grant for Clinical Cancer Research (22-021)
Article History
Received: 19 January 2021
Accepted: 10 March 2021
First Online: 31 March 2021
Declarations
:
: Seiichiro Abe: Boston Scientific (personal fees), AstraZeneca (personal fees), Takeda Pharmaceutical (personal fees), Olympus (personal fees and research funding), FUJIFILM (personal fees and research funding), Kohei Takizawa: Takeda Pharmaceutical (personal fees), Otsuka Pharmaceutical (personal fees), EA Pharma (personal fees), Boston Scientific (personal fees), AstraZeneca (personal fees), Taiho Pharmaceutical (personal fees), Ichiro Oda: Otsuka Pharmaceutical (personal fees), Taiho Pharmaceutical (personal fees), Takeda Pharmaceutical (personal fees), Olympus (personal fees), FUJIFILM (Research funding), Junki Mizusawa: no conflict of interest, Tomohiro Kadota: no conflict of interest, Hiroyuki Ono: Otsuka Pharmaceutical (personal fees), Daiichi-Sankyo (personal fees), EA Pharma (personal fees), Boston Scientific (personal fees), AstraZeneca (personal fees), Olympus (personal fees), Noriaki Hasuike: No conflict of interest, Tomonori Yano: Olympus (personal fees and research funding), FUJIFILM (research funding), Yoshinobu Yamamoto: No conflict of interest, Yusuke Horiuchi: Olympus (personal fees), Kaken Pharmaceutical Co.,Ltd. (personal fees), Shinji Nagata: No conflict of interest, Takaki Yoshikawa: Taiho Pharmaceutical (personal fees), Chugai Pharmaceutical (personal fees), Ono Pharmaceutical (personal fees), Bristol-Myers Squibb (personal fees), MSD (personal fees), Daiichi Sankyo (personal fees), Eli Lilly (personal fees), Pfizer (personal fees), Johnson and Johnson (personal fees), Covidien (personal fees), Olympus (personal fees), TERUMO (personal fees), Nihon Kayaku (personal fees), Masanori Terashima: Taiho Pharmaceutical (personal fees), Chugai Pharmaceutical (personal fees), Ono Pharmaceutical (personal fees), Bristol-Myers Squibb (personal fees), Yakult Honsha (personal fees), Takeda Pharmaceutical (personal fees), Eli Lilly (personal fees), Pfizer (personal fees), Daiichi Sankyo (personal fees), Manabu Muto: Olympus (research funding), Ono Pharmaceutical (research funding).
Free to read: This content has been made available to all.